In view of the cancer characteristics of oxidative imbalance, studies have shown that AST enhances antioxidant defense and inhibits K562 leukemia cell cycle progression through the Nrf2 pathway; however, the specific role of ROS signaling in the anticancer effect of AST still needs further exploration. Here, NFE2L2 is linked to cancer.